Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.
Level 5 - mechanism / opinion, no new human data
Consensus guideline and expert opinion based on a review of limited primary evidence
PubMed 28100251 · doi:10.1186/s13023-016-0522-z
What was done
Representatives from the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives reviewed available clinical literature to develop consensus guidelines for aromatic L-amino acid decarboxylase (AADC) deficiency. Recommendations covering clinical diagnosis, laboratory workup, neuroimaging, electroencephalography, and medical and non-medical therapies were formulated using SIGN and GRADE methodology.
What was found
The abstract reports no quantitative results, statistical measures, or effect sizes. It reports the establishment of practical consensus recommendations across diagnostic domains (clinical, laboratory, imaging, electroencephalography) and management strategies (pharmacological and non-pharmacological), along with identified priorities for future research.
Why it matters
AADC deficiency is an ultra-rare, severe neurometabolic disorder; these international consensus recommendations provide standardized guidance for clinical identification and multidisciplinary care where definitive trial evidence is scarce.
Limits
Primary clinical evidence was explicitly limited, requiring reliance on expert consensus. The abstract does not specify the number of included studies, patient counts, or specific treatment regimens.
Cited by
- supports Vitamin B6 is required for the enzymatic conversion of tryptophan into serotonin, which is subsequently converted into melatonin.